# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- Reuters
Novavax's updated JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3Novavax's...
B of A Securities analyst Alec Stranahan maintains Novavax (NASDAQ:NVAX) with a Neutral and raises the price target from $12...
-Reuters
Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their ...